Table 1.
Kinetics of IgM Mab-binding to recombinant gp160 and inhibition of HIV-1 transcytosisacross Caco-2-IgR+ cells.
| HIV-1 gp120 V3 specific | Time (h) | ELISA | Inhibition of HIV-1 transcytosis | ||
|---|---|---|---|---|---|
| Rgp160 binding (OD)* | HIV-1 IIIB (SI)** | HIV-1 6794 (SI) | HIV-1 6727 (NSI) | ||
| monoclonal antibodies | |||||
| MO96 | 0 | 0.010/0.008 | |||
| 14 | 0.140/0.111 | 87%/94% | 90%/70% | 25%/31% | |
| 24 | 0.652/0.596 | 87%/94%/91% | 90%/70%/76% | 25%/31%/35% | |
| MO97 | 0 | 0.009/0.010 | |||
| 14 | 0.151/0.148 | 23%/13% | 38%/0% | 1%/-5% | |
| 24 | 0.497/0.483 | 23%/13%/26% | 28%/10%/30% | 1%/-5%/0% | |
| MO99 | 0 | 0.011/0.012 | |||
| 14 | 0.201/0.209 | 83%/79% | 68%/70% | 41%/36% | |
| 24 | 0.599/0.604 | 83%/79%/84% | 88%/80%/91% | 41%/36%/35% | |
| MO101 | 0 | 0.014/0.011 | |||
| 14 | 0.166/0.144 | 88%/93% | 91%/77% | 5%/15% | |
| 24 | 0.552/0.505 | 88%/93%/89% | 91%/77%/90% | 5%/15%/65 | |
| MO86 | 0 | 0.007/0.009 | |||
| 14 | 0.103/0.098 | 35%/36% | 3%/4% | 10%/13% | |
| 24 | 0.393/0.402 | 35%/35%/36% | 3%/4%/3% | 11%/13%/9% | |
| Control IgM | |||||
| monoclonal antibody | |||||
| MO6 | 0 | 0.016/0.009 | |||
| 14 | 0.020/0.011 | 44%/0% | 11%/2% | 18%/22% | |
| 24 | 0.028/0.014 | 34%/0%/1% | 11%/2%/0% | 18%/22%/5% | |
| Medium | 0 | 0.014/0.010 | |||
| 14 | 0.020/0.012 | 0%/0% | 1%/0% | 0%/0% | |
| 24 | 0.018/0.012 | 0%/0%/05 | 1%/0%/0% | 0%/0%/0% | |
*Apical transwell culture medium collected and tested for anti-gp160 IgM binding activity at 0–24 hours by ELISA.
**Inhibition of HIV-1 p24 gag antigen in the basolateral transwell culture medium in the presence of anti-gp120 V3 Mabs compared with wells with control IgM or without antibodies.